Aimmune Therapeutics

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

Company Growth (employees)
Brisbane, US
Size (employees)
122 (est)+20%
Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US

Aimmune Therapeutics Office Locations

Aimmune Therapeutics has offices in Brisbane and Greater London
Brisbane, US (HQ)
200 8000 Marina Blvd
Greater London, GB
344-354 Grays Inn Rd
Show all (2)

Aimmune Therapeutics Financials and Metrics

Aimmune Therapeutics Financials


Net income (Q2, 2017)

(32.5 m)

EBIT (Q2, 2017)

(33 m)

Market capitalization (16-Feb-2018)

1.9 b

Cash (30-Jun-2017)

84.5 m
Aimmune Therapeutics's current market capitalization is $1.9 b.
USDFY, 2015FY, 2016

R&D expense

19.8 m54.6 b

General and administrative expense

16.2 m26.9 b

Operating expense total

36 m81.5 b


(36 m)(81.5 b)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

3.1 m3.9 m10 m11.8 m15.9 m17.4 m22.2 m

General and administrative expense

4.2 m5.2 m5.7 m6.5 m6.4 m8.9 m10.8 m

Operating expense total

7.4 m9 m15.7 m18.3 m22.2 m26.3 m33 m


(7.4 m)(9 m)(15.7 m)(18.3 m)(22.2 m)(26.3 m)(33 m)
USDFY, 2015FY, 2016


76.7 m124 m


5.6 m2.7 m

Current Assets

197.5 m251.7 m


2.7 m10.4 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


58.5 m112.7 m65 m74.4 m76.9 m78.7 m84.5 m

Current Assets

60.6 m217.8 m185.2 m172.8 m152.6 m248.9 m242.6 m


1.3 m1.8 m3.7 m7 m9 m11.1 m13.1 m

Total Assets

62.1 m222.8 m199.9 m185.7 m173.7 m276.3 m256.4 m
USDFY, 2015FY, 2016

Net Income

(35.8 m)(80.8 m)

Depreciation and Amortization

115 k534 k


4 m

Accounts Payable

1.1 m(994 k)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9 m)(15.5 m)(18.1 m)(22.1 m)(25.9 m)

Accounts Payable

309 k1 m1.8 m1.3 m1.5 m1.7 m
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Aimmune Therapeutics Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Aimmune Therapeutics Market Value History

Aimmune Therapeutics's Web-traffic and Trends

Aimmune Therapeutics Online and Social Media Presence

Aimmune Therapeutics Company Life and Culture

You may also be interested in